DAIICHI SANKYO, INC.
π―π΅Japan
- Country
- π―π΅Japan
- Ownership
- Subsidiary
- Established
- 2010-01-01
- Employees
- 10K
- Market Cap
- $79B
- Website
- http://daiichisankyo.us
Combination Chemotherapy With CS-1008 to Treat Ovarian Cancer
Phase 2
Completed
- Conditions
- Ovarian Cancer Stage IVOvarian Cancer Stage IIIC
- Interventions
- First Posted Date
- 2009-07-24
- Last Posted Date
- 2021-04-08
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 24
- Registration Number
- NCT00945191
- Locations
- πΊπΈ
Univ. Alabama, Birmingham, Alabama, United States
πΊπΈBarnes Jewish Hospital, Saint Louis, Missouri, United States
πΊπΈUniversity of Oklahoma, Oklahoma City, Oklahoma, United States
Parallel-Group Comparison of Olmesartan (OLM), Amlodipine (AML) and Hydrochlorothiazid (HCTZ) in Hypertension
Phase 3
Completed
- Conditions
- Essential Hypertension
- Interventions
- First Posted Date
- 2009-06-18
- Last Posted Date
- 2019-01-10
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 2689
- Registration Number
- NCT00923091
Hydrochlorothiazide as add-on to Olmesartan/Amlodipine in Hypertension
Phase 3
Completed
- Conditions
- Essential Hypertension
- Interventions
- Drug: OLM 40mg-AML 10mg-Hydrochlorothiazide 12.5mgDrug: OLM 40mg-AML 10mg-Hydrochlorothiazide 25mg
- First Posted Date
- 2009-05-15
- Last Posted Date
- 2019-01-11
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 2204
- Registration Number
- NCT00902538
Efficacy and Safety of Olmesartan Medoxomil in Stage 1 and 2 Essential Hypertension
Phase 4
Completed
- Conditions
- Essential Hypertension
- Interventions
- First Posted Date
- 2009-04-30
- Last Posted Date
- 2009-06-03
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 144
- Registration Number
- NCT00890591
Extended Use Protocol for Participants With Cancer to Receive Continued Treatment With CS-7017
- First Posted Date
- 2009-04-15
- Last Posted Date
- 2020-09-28
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 2
- Registration Number
- NCT00881569
Evaluation of the Additional Efficacy, and Safety of Olmesartan Medoxomil 20mg / Hydrochlorothiazide 12.5mg in the Treatment of Chinese Patients With Mild to Moderate Essential Hypertension
Phase 3
Completed
- Conditions
- Essential Hypertension
- Interventions
- First Posted Date
- 2009-03-31
- Last Posted Date
- 2010-09-29
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 304
- Registration Number
- NCT00872586
Olmesartan Medoxomil Versus Losartan in Patients With Hypertension
Phase 3
Completed
- Conditions
- Essential Hypertension
- Interventions
- First Posted Date
- 2009-03-06
- Last Posted Date
- 2009-07-23
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 130
- Registration Number
- NCT00857285
- Locations
- π¨π³
Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
π¨π³Chung Shun Medical University Hospital, Taichung City, Taiwan
π¨π³National Taiwan University Hospital, Taipei, Taiwan
Olmesartan Medoxomil Versus Losartan Potassium in Patients With Mild to Moderate Essential Hypertension
Phase 3
Completed
- Conditions
- Essential Hypertension
- Interventions
- First Posted Date
- 2009-03-05
- Last Posted Date
- 2010-09-29
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 287
- Registration Number
- NCT00856271
Study of Carboplatin/Paclitaxel With or Without Investigational Drug (CS-7017) in Subjects With Metastatic Non-small Cell Lung Cancer
Phase 2
Completed
- Conditions
- Metastatic Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2008-12-10
- Last Posted Date
- 2020-05-13
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 111
- Registration Number
- NCT00806286
- Locations
- πΊπΈ
University Colorado Cancer Center, Aurora, Colorado, United States
πΊπΈGeorgetown Univ. Medical Center, Washington, District of Columbia, United States
πΊπΈSouthern Illinois Hematology/Oncology, Centralia, Illinois, United States
Effects of Multiple Doses of CS-8080 in Healthy Volunteers
- First Posted Date
- 2008-11-24
- Last Posted Date
- 2018-12-21
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 16
- Registration Number
- NCT00796575
- Locations
- πΊπΈ
MDS Pharma Services, Neptune, New Jersey, United States